Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps.

Hung Yun Lin, Heng Yuan Tang, Faith B. Davis, Shaker A. Mousa, Sandra Incerpi, Mary K. Luidens, Ran Meng, Paul J. Davis

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

The sodium/proton (Na/H) exchanger, Na,K-ATPase, and Ca2+-ATPase are membrane ion pumps whose basal activities may be regulated by local nongenomic actions of thyroid hormone and hormone analogues via a hormone receptor on plasma membrane integrin αvβ3. System A amino acid transport and the activity of P-glycoprotein (P-gp; ABCB1), a multidrug efflux pump, are also modulated by thyroid hormone and αvβ3. Where signal transduction has been studied, the presence of the hormone at the receptor is transduced by mitogen-activated protein kinase (MAPK) isoforms (ERK1/2; p38) or phosphatidylinositol 3-kinase into local actions. The existence of the cell surface receptor offers opportunities to pharmacologically modify actions of these important transport functions with nanoparticulate formulations of T4 and T3 that do not enter the cell. Such formulations may reverse complex intracellular accumulations of H+, Na+, and Ca2+ that occur in clinical settings such as ischemia. In addition, nanoparticulate tetraiodothyroacetic acid (tetrac), a thyroid hormone analogue that inhibits binding of T4 and T3 to integrin αvβ3 as well as certain other functions of the integrin, may reverse P-gp-dependent resistance to anti-cancer drugs in tumor cells.

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalDiscovery medicine
Volume14
Issue number76
Publication statusPublished - Sep 2012
Externally publishedYes

Fingerprint

Thyroid Hormones
Integrins
Cell Membrane
Hormones
Ions
Ion Pumps
Phosphatidylinositol 3-Kinase
Amino Acid Transport Systems
Sodium-Hydrogen Antiporter
Calcium-Transporting ATPases
Cell Surface Receptors
P-Glycoprotein
Mitogen-Activated Protein Kinases
Protons
Signal Transduction
Neoplasms
Protein Isoforms
Ischemia
Sodium
Membranes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lin, H. Y., Tang, H. Y., Davis, F. B., Mousa, S. A., Incerpi, S., Luidens, M. K., ... Davis, P. J. (2012). Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps. Discovery medicine, 14(76), 199-206.

Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps. / Lin, Hung Yun; Tang, Heng Yuan; Davis, Faith B.; Mousa, Shaker A.; Incerpi, Sandra; Luidens, Mary K.; Meng, Ran; Davis, Paul J.

In: Discovery medicine, Vol. 14, No. 76, 09.2012, p. 199-206.

Research output: Contribution to journalReview article

Lin, HY, Tang, HY, Davis, FB, Mousa, SA, Incerpi, S, Luidens, MK, Meng, R & Davis, PJ 2012, 'Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps.', Discovery medicine, vol. 14, no. 76, pp. 199-206.
Lin HY, Tang HY, Davis FB, Mousa SA, Incerpi S, Luidens MK et al. Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps. Discovery medicine. 2012 Sep;14(76):199-206.
Lin, Hung Yun ; Tang, Heng Yuan ; Davis, Faith B. ; Mousa, Shaker A. ; Incerpi, Sandra ; Luidens, Mary K. ; Meng, Ran ; Davis, Paul J. / Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps. In: Discovery medicine. 2012 ; Vol. 14, No. 76. pp. 199-206.
@article{27e91012a5234da1810e5a11cdaf2d1b,
title = "Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps.",
abstract = "The sodium/proton (Na/H) exchanger, Na,K-ATPase, and Ca2+-ATPase are membrane ion pumps whose basal activities may be regulated by local nongenomic actions of thyroid hormone and hormone analogues via a hormone receptor on plasma membrane integrin αvβ3. System A amino acid transport and the activity of P-glycoprotein (P-gp; ABCB1), a multidrug efflux pump, are also modulated by thyroid hormone and αvβ3. Where signal transduction has been studied, the presence of the hormone at the receptor is transduced by mitogen-activated protein kinase (MAPK) isoforms (ERK1/2; p38) or phosphatidylinositol 3-kinase into local actions. The existence of the cell surface receptor offers opportunities to pharmacologically modify actions of these important transport functions with nanoparticulate formulations of T4 and T3 that do not enter the cell. Such formulations may reverse complex intracellular accumulations of H+, Na+, and Ca2+ that occur in clinical settings such as ischemia. In addition, nanoparticulate tetraiodothyroacetic acid (tetrac), a thyroid hormone analogue that inhibits binding of T4 and T3 to integrin αvβ3 as well as certain other functions of the integrin, may reverse P-gp-dependent resistance to anti-cancer drugs in tumor cells.",
author = "Lin, {Hung Yun} and Tang, {Heng Yuan} and Davis, {Faith B.} and Mousa, {Shaker A.} and Sandra Incerpi and Luidens, {Mary K.} and Ran Meng and Davis, {Paul J.}",
year = "2012",
month = "9",
language = "English",
volume = "14",
pages = "199--206",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "76",

}

TY - JOUR

T1 - Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps.

AU - Lin, Hung Yun

AU - Tang, Heng Yuan

AU - Davis, Faith B.

AU - Mousa, Shaker A.

AU - Incerpi, Sandra

AU - Luidens, Mary K.

AU - Meng, Ran

AU - Davis, Paul J.

PY - 2012/9

Y1 - 2012/9

N2 - The sodium/proton (Na/H) exchanger, Na,K-ATPase, and Ca2+-ATPase are membrane ion pumps whose basal activities may be regulated by local nongenomic actions of thyroid hormone and hormone analogues via a hormone receptor on plasma membrane integrin αvβ3. System A amino acid transport and the activity of P-glycoprotein (P-gp; ABCB1), a multidrug efflux pump, are also modulated by thyroid hormone and αvβ3. Where signal transduction has been studied, the presence of the hormone at the receptor is transduced by mitogen-activated protein kinase (MAPK) isoforms (ERK1/2; p38) or phosphatidylinositol 3-kinase into local actions. The existence of the cell surface receptor offers opportunities to pharmacologically modify actions of these important transport functions with nanoparticulate formulations of T4 and T3 that do not enter the cell. Such formulations may reverse complex intracellular accumulations of H+, Na+, and Ca2+ that occur in clinical settings such as ischemia. In addition, nanoparticulate tetraiodothyroacetic acid (tetrac), a thyroid hormone analogue that inhibits binding of T4 and T3 to integrin αvβ3 as well as certain other functions of the integrin, may reverse P-gp-dependent resistance to anti-cancer drugs in tumor cells.

AB - The sodium/proton (Na/H) exchanger, Na,K-ATPase, and Ca2+-ATPase are membrane ion pumps whose basal activities may be regulated by local nongenomic actions of thyroid hormone and hormone analogues via a hormone receptor on plasma membrane integrin αvβ3. System A amino acid transport and the activity of P-glycoprotein (P-gp; ABCB1), a multidrug efflux pump, are also modulated by thyroid hormone and αvβ3. Where signal transduction has been studied, the presence of the hormone at the receptor is transduced by mitogen-activated protein kinase (MAPK) isoforms (ERK1/2; p38) or phosphatidylinositol 3-kinase into local actions. The existence of the cell surface receptor offers opportunities to pharmacologically modify actions of these important transport functions with nanoparticulate formulations of T4 and T3 that do not enter the cell. Such formulations may reverse complex intracellular accumulations of H+, Na+, and Ca2+ that occur in clinical settings such as ischemia. In addition, nanoparticulate tetraiodothyroacetic acid (tetrac), a thyroid hormone analogue that inhibits binding of T4 and T3 to integrin αvβ3 as well as certain other functions of the integrin, may reverse P-gp-dependent resistance to anti-cancer drugs in tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=84874158798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874158798&partnerID=8YFLogxK

M3 - Review article

C2 - 23021374

AN - SCOPUS:84874158798

VL - 14

SP - 199

EP - 206

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 76

ER -